All PlansAdministrativeMedium impact
Voluntary nationwide recall: Dextrose (Baxter – August 2026)
UPMC Health Plan·Pharmacy, Critical Care·Pharmacy
We identified it
Sep 12, 2026
Summary
Baxter International is recalling one lot (Y495066) of 70% Dextrose Injection due to stainless steel particles that could cause local irritation, swelling, or life-threatening blood clots. The billing team must identify claims associated with this recalled lot, communicate with providers and patients, and potentially process adjustments or denials for affected administrations. As of August 25, 2026, no adverse events have been reported.
Action Required
Immediately: Billing team and providers must identify any patient claims or encounters involving lot Y495066 of Baxter 70% Dextrose Injection (August 2026 recall). Contact patients who received this lot and coordinate with providers to determine if claims need to be voided, adjusted, or flagged for review. Notify the clinical team to verify lot numbers in the pharmacy system and EMR. If claims have already been submitted and paid for affected administrations, prepare for potential recoupment or adjustment requests. Monitor the FDA website and Baxter Healthcare Center (888-229-0001) for updates on patient harm reports or expanded recall scope. Document all actions taken in patient records and billing system for compliance and audit purposes.